Bevacizumab
證據等級: L5 | 預測適應症: 10 個
## 藥師評估報告
Bevacizumab：從多種癌症到會厭腫瘤
一句話總結
Bevacizumab 原為抗血管新生的癌症標靶藥物，用於轉移性大腸直腸癌、肺癌、卵巢癌等多種惡性腫瘤，TxGNN 預測其可能對會厭腫瘤(epiglottis neoplasm)有治療潛力。
快速總覽
| 項目 | 內容 | |------|------| | 原適應症 | 轉移性大腸直腸癌、乳癌、非小細胞肺癌、卵巢癌、子宮頸癌、神經膠母細胞瘤等 | | 預測新適應症 | epiglottis neoplasm、benign neoplasm of tongue、tumor of testis and paratestis、benign neoplasm of hypopharynx、benign neoplasm of floor of mouth、cervical neuroblastoma、cystic neoplasm、nasal cavity inverting papilloma、mesenchymoma、schwannoma of jugular foramen | | TxGNN 預測分數 | 99.90% | | 證據等級 | L5 (僅預測) | | 台灣上市 | 已上市 | | 許可證數 | 多張 (Avastin、MVASI、ABEVMY、Vegzelma等) | | 建議決策 | Explore |
預測適應症詳細分析
1. epiglottis neoplasm L5 99.90% 主要分析
2. benign neoplasm of tongue L4 99.90%
相關文獻（7 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 39927612 | 2025 | Article | Expert opinion on pharmacother | Oral mucosal toxicities in oncology. |
| 16496361 | 2006 | Article | Journal of surgical oncology | Re: Correlational of oral tongue cancer inversion with matrix metalloproteinases... |
| 20187015 | 2010 | Article | Head & neck | Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the bas... |
| 40418990 | 2025 | Article | Journal of controlled release | Multi-modality imaging for precise intra-arterial delivery of mRNA, AAVs, and an... |
| 21236594 | 2012 | Article | International journal of radia | Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretrea... |
| 18691881 | 2008 | Article | European journal of cancer (Ox | Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine... |
| 21744483 | 2011 | Article | Pediatric blood & cancer | Antiangiogenic treatment as a pre-operative management of alveolar soft-part sar... |
3. tumor of testis and paratestis L5 99.90%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
4. benign neoplasm of hypopharynx L5 99.90%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
5. benign neoplasm of floor of mouth L3 99.90%
臨床試驗（1 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT01552434 | PHASE1 | ACTIVE_NOT_RECRUITING | 155 | A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valpr... |
相關文獻（2 篇）
6. cervical neuroblastoma L2 99.89%
臨床試驗（5 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT00101348 | PHASE1, PHASE2 | COMPLETED | 66 | A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetu... |
| NCT00492089 | PHASE2 | COMPLETED | 11 | A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage |
| NCT01096381 | N/A | TERMINATED | 8 | A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Ind... |
| NCT06047379 | PHASE1, PHASE2 | RECRUITING | 134 | An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 i... |
| NCT00023959 | PHASE1 | COMPLETED | 39 | A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vas... |
相關文獻（2 篇）
7. cystic neoplasm L1 99.89%
臨床試驗（8 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT00101348 | PHASE1, PHASE2 | COMPLETED | 66 | A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetu... |
| NCT00492089 | PHASE2 | COMPLETED | 11 | A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage |
| NCT00565851 | PHASE3 | ACTIVE_NOT_RECRUITING | 1052 | A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (... |
| NCT01096381 | N/A | TERMINATED | 8 | A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Ind... |
| NCT03074513 | PHASE2 | ACTIVE_NOT_RECRUITING | 133 | A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and B... |
| NCT00381797 | PHASE2 | COMPLETED | 97 | Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recu... |
| NCT00324987 | PHASE3 | TERMINATED | 12 | A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-70486... |
| NCT00023959 | PHASE1 | COMPLETED | 39 | A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vas... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 40644648 | 2025 | Article | Journal of clinical oncology : | Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous O... |
| 38328890 | 2024 | Article | Future oncology (London, Engla | Efficacy and safety of bevacizumab in patients with low-grade serous ovarian can... |
| 37657955 | 2023 | Article | Clinical colorectal cancer | Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresecta... |
| 27412268 | 2016 | Article | Cancer | Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine a... |
| 18796376 | 2008 | Article | Clinical & translational oncol | Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian ca... |
| 27141073 | 2016 | Article | Annals of oncology : official | Mucinous epithelial ovarian carcinoma. |
| 40141188 | 2025 | Article | International journal of molec | Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and t... |
| 24978709 | 2014 | Article | International journal of gynec | Bevacizumab shows activity in patients with low-grade serous ovarian and primary... |
| 37754507 | 2023 | Article | Current oncology (Toronto, Ont | Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review. |
| 29752717 | 2018 | Article | International journal of cance | Tumor progression and metastatic dissemination in ovarian cancer after dose-dens... |
| 27498762 | 2016 | Article | Scientific reports | A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts ... |
| 31989304 | 2020 | Article | Current oncology reports | Low-grade Serous Tumors: Are We Making Progress? |
| 27154293 | 2016 | Article | Journal of translational medic | GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseu... |
| 32494876 | 2020 | Article | Current oncology reports | First-Line Management of Advanced High-Grade Serous Ovarian Cancer. |
| 22343232 | 2012 | Article | Clinical obstetrics and gyneco | First-line chemotherapy in epithelial ovarian cancer. |
| 18165643 | 2008 | Article | Journal of clinical oncology : | Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophospha... |
| 26241347 | 2015 | Article | Current opinion in oncology | Low-grade epithelial ovarian cancer: a number of distinct clinical entities? |
| 30030657 | 2019 | Article | International journal of clini | Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment f... |
| 39013870 | 2024 | Article | Nature communications | Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: ... |
| 40700681 | 2025 | Article | Journal of clinical oncology : | Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemothera... |
8. nasal cavity inverting papilloma L2 99.89%
臨床試驗（4 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT00101348 | PHASE1, PHASE2 | COMPLETED | 66 | A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetu... |
| NCT00492089 | PHASE2 | COMPLETED | 11 | A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage |
| NCT01096381 | N/A | TERMINATED | 8 | A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Ind... |
| NCT00023959 | PHASE1 | COMPLETED | 39 | A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vas... |
9. mesenchymoma L5 99.89%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
10. schwannoma of jugular foramen L5 99.89%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
台灣上市資訊
Bevacizumab 在台灣有多項藥品許可證：
- Avastin (癌思停) - 羅氏
- MVASI - 安進
- ABEVMY - 三星生技
- Vegzelma (艾法施) - 信東
核准適應症涵蓋：
- 轉移性大腸直腸癌
- 轉移性乳癌(HER2 陰性)
- 非小細胞肺癌
- 神經膠母細胞瘤
- 卵巢上皮細胞癌
- 子宮頸癌
安全性考量
常見副作用
- 高血壓
- 蛋白尿
- 出血事件
- 傷口癒合延遲
嚴重警語
- 胃腸道穿孔風險
- 動脈血栓栓塞事件
- 需監測血壓及蛋白尿
藥物交互作用
與其他抗癌藥物併用時需注意骨髓抑制加成效應。
藥物-疾病注意事項 (DDSI)
資料來源：DDInter 2.0（原文內容請參閱該網站）
Hemorrhage 🟡 Moderate
- 應謹慎使用本藥物。風險包括：出血。必要時應停止治療。
高血壓 🟡 Moderate
- 可能有嚴重不良反應。必要時應停止治療。
Posterior Leukoencephalopathy Syndrome 🟡 Moderate
- 風險包括：癲癇發作。必要時應停止治療。
Proteinuria 🟡 Moderate
- 需定期監測。可能有嚴重不良反應。必要時應停止治療。
Thromboembolism 🟡 Moderate
- 應謹慎使用本藥物。風險包括：血栓。可能有致命風險。必要時應停止治療。
Fistula 🟢 Minor
- 可能有致命風險。必要時應停止治療。
Peptic Ulcer Perforation 🟢 Minor
- 出現症狀時應考慮停藥。
結論與下一步
證據等級：L5 (僅 TxGNN 預測，無臨床證據)
建議：
- 會厭腫瘤為罕見疾病，目前無標準治療方案時可考慮探索性使用
- 建議優先參考頭頸部鱗狀細胞癌的 bevacizumab 使用經驗
- 若考慮臨床應用，應在腫瘤專科醫師指導下進行
下一步研究方向：
- 回顧性分析頭頸部癌症病例中會厭受累的治療反應
- 考慮個案報告或小規模臨床試驗評估可行性
相關藥物報告
- Voriconazole - 證據等級 L5
- Disopyramide - 證據等級 L5
- Trifluoperazine - 證據等級 L5
- Povidone - 證據等級 L5
- Etanercept - 證據等級 L5
用 AI 幫我深入分析
想進一步了解這個藥物的老藥新用潛力嗎？點擊下方按鈕，直接開啟 AI 助手進行分析。
Claude：點擊後會複製提問並開啟新視窗，請按 Ctrl+V（Mac: Cmd+V）貼上
ChatGPT：點擊後直接開啟並自動帶入提問
引用本報告
如需引用本報告，請使用以下格式：
APA 格式：
TwTxGNN. (2026). Bevacizumab老藥新用驗證報告. https://twtxgnn.yao.care/drugs/bevacizumab/
BibTeX 格式：
@misc{twtxgnn_bevacizumab,
title = {Bevacizumab老藥新用驗證報告},
author = {TwTxGNN Team},
year = {2026},
url = {https://twtxgnn.yao.care/drugs/bevacizumab/}
}
免責聲明
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
歡迎分享您對本報告的看法、補充資訊或提出問題。討論內容會同步到 GitHub Discussions。 需要 GitHub 帳號才能留言。